Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine vs hydromorphone for gastrointestinal tolerability after major abdominal surgery
ChiCTR2500111214Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oliceridine in acute postoperative pain (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of postoperative nausea and vomiting (PONV) within 72 hours postoperatively. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
oliceridine
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on ChiCTR2500111214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111214.